Mosapramine

This classification denotes an antidepressant agent with the molecular formula C28H35ClN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04UZQ7O9SJ, chemically known as (- )-1-(3-(3-chloro-10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)hexahydrospiro(imidazo(1,2-a)pyridine-3(2h),4-piperidin)-2-one. but generally known as mosapramine, which bears US NIH Compound Identifier 4257. European Medicines Agency schedules Mosapramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09073MIG. The term MOSAPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules mosapramine in its Anatomical Therapeutic Chemical (ATC) Classification. MOSAPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mosapramine under HS 29333999 and SITC 51574. As of Q4 2014, MOSAPRAMINE remains the US FDA Preferred Term for this commodity. Mosapramine bears US NLM identifiers UMLS ID C0208216 and NCI Concept Code C66203. SMILES: Clc1cc2N(CCCN3CCC4(N5C(NC4=O)CCCC5)CC3)c3c(CCc2cc1)cccc3.